PT  - JOURNAL ARTICLE
AU  - SHOTARO YASUOKA
AU  - TAKESHI YUASA
AU  - RYO FUJIWARA
AU  - YOSHINOBU KOMAI
AU  - NOBORU NUMAO
AU  - SHINYA YAMAMOTO
AU  - YUKIHIRO KONDO
AU  - JUNJI YONESE
TI  - Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer
AID  - 10.21873/anticanres.14671
DP  - 2020 Nov 01
TA  - Anticancer Research
PG  - 6493--6497
VI  - 40
IP  - 11
4099  - http://ar.iiarjournals.org/content/40/11/6493.short
4100  - http://ar.iiarjournals.org/content/40/11/6493.full
SO  - Anticancer Res2020 Nov 01; 40
AB  - Background/Aim: Tyrosine kinase inhibitors (TKI) and immune-checkpoint inhibitors (ICI) are treatment options for metastatic renal cell cancer (mRCC). However, the treatment options after nivolumab are unclear. Patients and Methods: The medical records of 57 consecutive Japanese mRCC patients who underwent treatment with axitinib were reviewed. Among those, 17 patients received axitinib treatment after nivolumab and 40 patients received axitinib treatment after other chemotherapy regimens except nivolumab. Results: Of the 57 patients with mRCC, only 17 underwent axitinib therapy after nivolumab. Among these 17 patients, the objective response rate (ORR) and median tumor shrinkage rate were 56.3% and −30%, respectively. They were significantly better in patients who underwent axitinib therapy after nivolumab than after other therapies (p=0.026 and p=0.012, respectively). However, all 17 patients experienced some adverse events and nine patients (52.9%) required a dose reduction or axitinib treatment interruption. Conclusion: Axitinib therapy after the immune checkpoint inhibitor nivolumab showed good efficacy with a moderate risk of adverse events. Careful management by skilled professionals may be required.